On December 29, Turkish media reported that Turkish President Tayyip Erdogan said on Monday that Turkey will receive the first batch of COVID-19 vaccines developed by China Kexing Company this week, although doctors are waiting More comprehensive test results, but the Turkish government still focuses on the promotion of the vaccine. According to previous media reports, Turkey has agreed to purchase 50 million doses of Coxing’s CoronaVac vaccine, which is expected to be delivered by December 11, but delivery is facing delays.
Last week, Turkish researchers said that according to an interim analysis, the effective rate of Koxing vaccine was 91.25%. However, despite the Minister of Health Fahrettin Koca (Fahrettin Koca) said last week that “we can now be sure that this vaccine is effective and safe”, the trial data based on 29 infections is considered too limited to be finally approved.
Erdogan said at a press conference that Turkey has studied eight different vaccines and one of the studies has entered the final stage. He said: "We hope to receive the first batch of vaccines we purchased from China before the new year." According to the disclosure of vaccine efficiency data, Kexing is currently seeking to integrate data from Indonesia, Chile, Turkey and Brazil. Wait for the data of the global experiment in order to get a more complete experimental result situation. Previously, Brazil reported that the efficacy of the vaccine exceeded the 50% effectiveness threshold, but the specific data was not disclosed. The Brazilian medical staff who participated in the experiment privately disclosed to the media that the vaccine’s effectiveness is very high. 90%.
Two Turkish doctors told Reuters that it may take at least a few weeks if the test results of Coxing vaccine are to be conclusive, because the sample size needs to be increased.
Mustafa Cankurtaran, head of the Department of Geriatrics at Ankara Hassetpe Medical School, said: “Due to the lower proportion of placebos, the CoronaVac vaccine test in Cosing takes longer than Moderna and Pfizer's is longer."
said: "This means that it takes longer for COVID-19 cases to appear in the test population, and it takes longer to reach the statistically more important 40-50 positive cases."
Kankutaran added that the final result is likely to "require a one-month trial period."
Vedat Bulut, secretary general of the Turkish Medical Association, told Reuters that he expected a clearer picture soon. The Turkish Medical Association criticized Ankara for not doing enough in terms of transparency and containment measures related to the new crown pandemic this year. Z1z
Blut told the media: "At present, we do not have enough data to prove that this vaccine is effective and protective."
"When we get the expected (global) data, phase III will be carried out within two weeks. The results of clinical trials are integrated and researched, and then we will know whether this vaccine is effective and protective."
